Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer

NCT07192614 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07192614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07192614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 30, 2025
Completion date
March 29, 2029
Enrollment
52 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer